Merck’s established research and development capabilities could also enhance SpringWorks’ drug discovery and development processes, potentially leading to a more robust and diverse pipeline.

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.

The market capitalization of SpringWorks is $3.4 billion. A Merck representative announced that various options for the deal are being considered, which is expected to be concluded within a few weeks.

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: ... (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, ...

Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), relating to the proposed merger with Merck KGaA, Darmstadt, Germany. Under the terms of the agreement, ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibitors in efficacy, safety, and patient-friendly delivery. The evolving NF1 landscape highlights how innovation ...

BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 71 hedge fund portfolios held SpringWorks Therapeutics, Inc ...